DIA anaylsis for human plasma in MI patitents

A total of 386 patients were enrolled from May 2019 to May 2022 in TEDA International Cardiovascular Hospital, Tianjin, China. This study was approved by Institutional Review Board (IRB) at TEDA International cardiovascular hospital, Tianjin, china, and informed consent was obtained from all patients recruited in this study. All patients were informed of all the aspects of the study. STEMI refers to designate MI in patients with chest discomfort or other ischaemia symptoms, who develop new ST-segment elevations in two contiguous leads or new bundle branch blocks with ischaemia repolarization patterns as an ST-elevation MI. Patients present without ST-segment elevation were designated as having NSTEMI (13). Patients without ST-segment elevation exert symptoms suggestive of cardiac ischemia without elevated biomarker values can be diagnosed as having UA(5, 13). The inclusion and exclusion criteria of STEMI, NSTEMI and UA patients were according to the guidelines outlined by the 2017 European Society of Cardiology (ESC)(14). The control subjects were recruited from patients that underwent conventional coronary angiography for atypical chest discomfort(15). Finally, 182 patients were included in STEMI group, 80 in NSTEMI group, and 62 in UA group. Additionally, after matching the age and gender, 62 subjects with normal coronary arteries were identified as Control (CON). All treatment and management measures were monitored by the attending physicians. Further, the clinical information was collected, including age, gender, body mass index (BMI), risk factors such as hypertension, diabetes, dyslipidemia, and smoke. The vessel lesion and laboratory data were also collected.